Kura Oncology (KURA) has released an update.
Preliminary clinical data from KOMET-007, a Phase 1 trial of ziftomenib for treating acute myeloid leukemia, showed promising results with a 100% complete remission rate in newly diagnosed patients and a 53% overall response rate in refractory/relapsed patients. Ziftomenib was well tolerated with no significant adverse effects. As the trial progresses, the 200 mg dose has been approved for further study, with a Phase 1b expansion planned. The Company expects to complete patient enrollment for the Phase 2 trial of ziftomenib by mid-year and has sufficient funds to operate into 2027.
For further insights into KURA stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
